
No results matched your search
By Deena Beasley
(Reuters) - Amgen Inc (NASDAQ:AMGN) on Tuesday reported higher-than-expected fourth-quarter profit as sales rose and tax expense fell, but competition for older medicines is growing and the drugmaker forecast 2019 earnings below Wall Street estimates.
For the full-year, Amgen projected adjusted earnings of $13.10 to $14.30 per share on revenue of $21.8 billion to $22.9 billion. Wall Street analysts, on average, had forecast $14.61 per share on revenue $22.9 billion, according to IBES data from Refinitiv.
The world’s largest biotechnology company posted a net profit of $1.93 billion, or $3.01 per share, compared with a net loss of $4.26 billion, or $5.89 per share, a year ago, when it took a large charge related to changes in U.S. corporate tax laws.
Excluding items, Amgen said it had adjusted earnings for the quarter of $3.42 per share. Analysts, on average, expected $3.27 per share.
Total revenue for the quarter rose 7 percent to $6.23 billion, beating the average analyst estimate of $5.84 billion.
The rise in sales was driven largely by increased demand for medicines such as cancer drug Kyprolis, cholesterol fighter Repatha and osteoporosis treatment Prolia.
ZURICH (Reuters) - The head of Switzerland's financial regulator FINMA questioned Credit Suisse (SIX:CSGN) over risks in its dealings with now-insolvent finance firm Greensill...
By David Shepardson, Hyunjoo Jin and Heekyong Yang WASHINGTON/SEOUL (Reuters) -South Korean battery makers LG Energy Solution and SK Innovation Co agreed on Sunday to settle...
By James Davey LONDON (Reuters) - After more than three months of enforced closure due to the COVID-19 pandemic, non-essential stores in England reopen their doors on Monday,...
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.